CR1 · Western blot design guide

CR1 Western Blot Planning Guide

Plan a CR1 Western blot around the catalog-observed 223.7 kDa band, image-backed A01022-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use

Western blot protocol sheet for CR1 (CR1): expected band 223.7 kDa, antibody A01022-1, and PMC-cited SDS-PAGE protocol steps

Band Protocols Controls Antibodies

CR1 Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running

	Expected band	223.7 kDa
	Observed band	Not reported — verify product WB image
	Gel	4-12% gradient
	Positive control ⓘ	Spleen
	Negative control ⓘ	Bronchus

Important caveats

Reasons your observed band may differ from the expected size.

ⓘ	Calculated mass	223.7 kDa
ⓘ	Localization	Membrane
ⓘ	Processing / PTM	Record-dependent
ⓘ	Reactivity	Human

Sample controls for CR1 Western blot

🧪Use Spleen as the first positive-control candidate and Bronchus as the HPA Not detected negative candidate.

Positive control: Spleen (Medium)

Negative control: Bronchus (Not detected)

HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for CR1

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Spleen	Reported tissue cells	Medium	Protein (HPA)	HPA →
Kidney	Reported tissue cells	Medium	Protein (HPA)	HPA →
Appendix	Reported tissue cells	Medium	Protein (HPA)	HPA →
Bone marrow	Reported tissue cells	Medium	Protein (HPA)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Bronchus	Reported tissue cells	Not detected	Protein (HPA)	HPA →
Caudate	Reported tissue cells	Not detected	Protein (HPA)	HPA →

Section 1

What Is the Expected CR1 Western Blot Band Size?

Use the product-observed 223.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
223.7 kDa	Matches the authoritative product WB observation.
223.7 kDa calculated	Use as UniProt context, not as a replacement observed band.
Unexpected additional signal	Do not assign identity without orthogonal positive/negative controls.

💡Expected CR1 appearancePlan around 223.7 kDa and keep the calculated mass as supporting context.

How each factor affects band size
Catalog-observed band	223.7 kDa; use this as the primary experimental expectation.
Calculated mass	223.7 kDa from UniProt P17927; retain as context.
Gel selection	4-12% gradient; shared with the recommended protocol and poster.
Specificity check	Compare the lead HPA positive and negative controls with A01022-1.

Why is my band missing or off?
Situation	Likely cause	Next action
223.7 kDa	Matches the authoritative product WB observation.	Confirm with orthogonal controls and the linked product record.
Additional band	May reflect processing, modification, or non-specific signal.	Run a dilution series and compare positive/negative controls.
Weak signal	Target abundance or transfer may be limiting.	Verify transfer, increase positive-control abundance, and bracket exposure.

Sources: UniProt P17927 Human Protein Atlas product datasheet (A01022-1)

Experiment evidence

Western blot images showing CR1 band

A01022-1 · CR1 — observed 223.7 kDa WB validation

A01022-1 · CR1Observed 223.7 kDa · product-specific WB image

← swipe / scroll for more images →

Real WB data behind the band-size expectations in this section.

Section 2

Real Curated CR1 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysate	Appendix
Gel %	4-12% gradient
Load	20-30 µg total protein per lane
Transfer	Wet/tank, extended transfer
Membrane	0.45 µm PVDF
Blocking	5% non-fat milk or 5% BSA in TBST
Primary	A01022-1 at datasheet starting dilution
Primary incubation	Overnight at 4 °C with gentle agitation
Secondary	Species-matched HRP conjugate at validated dilution
Wash	3 × 5 min in TBST
Detection	Chemiluminescent substrate
Exposure	Bracket exposures to avoid saturation

Section 4

Advanced CR1 Western Blot Tips

Deeper troubleshooting and optimisation questions for CR1, answered from its protein features.

Which band should guide the blot?

Use 223.7 kDa, the observation attached to the authoritative A01022-1 WB record.

How should calculated mass be interpreted?

Treat the UniProt calculated mass as context; it does not replace the catalog-observed 223.7 kDa expectation.

Which positive control should I start with?

Start with Spleen, the lead HPA protein-expression candidate.

Which negative control is defensible?

Use Bronchus as an orthogonal HPA Not detected candidate.

Which gel should I use?

Use 4-12% gradient consistently across the quick facts, protocol table, and poster.

What transfer method to use for CR1 Western blot?

Use the transfer method in the recommended protocol and verify transfer before blocking.

How should A01022-1 be started?

Start at the linked datasheet condition and run a three-point primary-antibody dilution test.

Which publication-derived protocols can I compare?

Compare only the supplied target-verified records: PMC4833428, PMC6231989, PMC3265835.

Boster reagents

CR1 Western Blot Reagents

Human-reactive CR1 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for CR1 using A01022-1; observed band 223.7 kDa

Anti-CD35/CR1 Antibody Picoband®

Cat # A01022-1

Reactivity: Human

View product →

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.